mTORC1 and mTORC2 in cancer and the tumor microenvironment

Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma

(2016) Emmanuel Seront et al.   BJU INTERNATIONAL

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

(2016) Joaquin Mateo et al.   BRITISH JOURNAL OF CANCER

mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells

(2016) Raju V. Pusapati et al.   CANCER CELL

Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers

(2016) M. Morrison Joly et al.   CANCER RESEARCH

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2016) S. O. Dolly et al.   CLINICAL CANCER RESEARCH

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer

(2016) Thomas Powles et al.   EUROPEAN UROLOGY

A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer

(2016) Josep María del Campo et al.   GYNECOLOGIC ONCOLOGY

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

(2016) Thomas Powles et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt

(2016) Jinfang Zhang et al.   MOLECULAR CELL

The ever-expanding role of HIF in tumour and stromal biology

(2016) Edward L. LaGory et al.   NATURE CELL BIOLOGY

mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle

(2016) I. Ben-Sahra et al.   SCIENCE

Mammalian Target of Rapamycin Complex 2 Controls CD8 T Cell Memory Differentiation in a Foxo1-Dependent Manner

(2016) Lianjun Zhang et al.   Cell Reports

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

(2015) Johanna C. Bendell et al.   CANCER

Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling

(2015) Shaogang Sun et al.   CANCER CELL

Plasticity beyond Cancer Cells and the “Immunosuppressive Switch”

(2015) Zvi Granot et al.   CANCER RESEARCH

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1

(2015) Wilhelm Palm et al.   CELL

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

(2015) Sonja Kleffel et al.   CELL

Multiple amino acid sensing inputs to mTORC1

(2015) Mitsugu Shimobayashi et al.   CELL RESEARCH

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

(2015) B. Basu et al.   CLINICAL CANCER RESEARCH

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

(2015) P. Munster et al.   CLINICAL CANCER RESEARCH

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

(2015) G. I. Shapiro et al.   CLINICAL CANCER RESEARCH

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

(2015) Johanna C. Bendell et al.   INVESTIGATIONAL NEW DRUGS

mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation

(2015) Kristen N. Pollizzi et al.   JOURNAL OF CLINICAL INVESTIGATION

The role for autophagy in cancer

(2015) Eileen White   JOURNAL OF CLINICAL INVESTIGATION

mTOR: a pharmacologic target for autophagy regulation

(2015) Young Chul Kim et al.   JOURNAL OF CLINICAL INVESTIGATION

Regulation of Endothelial Cell Proliferation and Vascular Assembly through Distinct mTORC2 Signaling Pathways

(2015) Shan Wang et al.   MOLECULAR AND CELLULAR BIOLOGY

Molecular Basis of the Rapamycin Insensitivity of Target Of Rapamycin Complex 2

(2015) Christl Gaubitz et al.   MOLECULAR CELL

Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma

(2015) Patrick Y. Wen et al.   NEURO-ONCOLOGY

CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks

(2015) F Guo et al.   ONCOGENE

Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP

(2015) S J H Ricoult et al.   ONCOGENE

Architecture of human mTOR complex 1

(2015) C. H. S. Aylett et al.   SCIENCE

Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1

(2015) S. Wang et al.   SCIENCE

Sestrin2 is a leucine sensor for the mTORC1 pathway

(2015) R. L. Wolfson et al.   SCIENCE

Differential regulation of mTORC1 by leucine and glutamine

(2015) J. L. Jewell et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors

(2015) H. Cheng et al.   Cancer Discovery

PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex

(2015) P. Liu et al.   Cancer Discovery

A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation

(2015) Guang Yang et al.   Cell Reports

mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis

(2015) Meghan M. Morrison et al.   PLoS Genetics

Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis

(2015) Maikel A. Farhan et al.   PLoS One

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

(2014) K. P. Papadopoulos et al.   CLINICAL CANCER RESEARCH

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

(2014) Carolyn D. Britten et al.   INVESTIGATIONAL NEW DRUGS

Nitrogen Source Activates TOR (Target of Rapamycin) Complex 1 via Glutamine and Independently of Gtr/Rag Proteins

(2014) Daniele Stracka et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors

(2014) Pasi A. Jänne et al.   Journal of Thoracic Oncology

Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma

(2014) Kyriakos P. Papadopoulos et al.   LEUKEMIA & LYMPHOMA

SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer

(2014) Jessica A. Gasser et al.   MOLECULAR CELL

The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex

(2014) Emily B Heikamp et al.   NATURE IMMUNOLOGY

Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors

(2013) Eeva M. Sommer et al.   BIOCHEMICAL JOURNAL

Requirement for Rictor in homeostasis and function of mature B lymphoid cells

(2013) K. Lee et al.   BLOOD

mTOR Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis

(2013) D. Roy et al.   CANCER RESEARCH

mTOR Complex 2 Controls Glycolytic Metabolism in Glioblastoma through FoxO Acetylation and Upregulation of c-Myc

(2013) Kenta Masui et al.   Cell Metabolism

Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2

(2013) Sean J. Humphrey et al.   Cell Metabolism

Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer

(2013) Sampurna Chatterjee et al.   JOURNAL OF CLINICAL INVESTIGATION

mTOR kinase structure, mechanism and regulation

(2013) Haijuan Yang et al.   NATURE

Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis

(2013) Pengda Liu et al.   NATURE CELL BIOLOGY

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy

(2013) M. Weiler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1

(2013) I. Ben-Sahra et al.   SCIENCE

Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis

(2013) A. M. Robitaille et al.   SCIENCE

Resolving Molecular Events in the Regulation of Meiosis in Male and Female Germ Cells

(2013) S. Kumar et al.   Science Signaling

The TSC-mTOR pathway regulates macrophage polarization

(2013) Vanessa Byles et al.   Nature Communications

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

(2013) J. M. Balko et al.   Cancer Discovery

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

(2012) B. Markman et al.   ANNALS OF ONCOLOGY

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

(2012) A Naing et al.   BRITISH JOURNAL OF CANCER

A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

(2012) Luis E. Raez et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Leucyl-tRNA Synthetase Is an Intracellular Leucine Sensor for the mTORC1-Signaling Pathway

(2012) Jung Min Han et al.   CELL

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

(2012) D. Mahadevan et al.   EUROPEAN JOURNAL OF CANCER

Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia

(2012) Keunwook Lee et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Leucyl-tRNA Synthetase Controls TORC1 via the EGO Complex

(2012) Grégory Bonfils et al.   MOLECULAR CELL

The translational landscape of mTOR signalling steers cancer initiation and metastasis

(2012) Andrew C. Hsieh et al.   NATURE

Dual Inhibition of the PI3K/mTOR Pathway Increases Tumor Radiosensitivity by Normalizing Tumor Vasculature

(2011) E. Fokas et al.   CANCER RESEARCH

Activation of mTORC2 by Association with the Ribosome

(2011) Vittoria Zinzalla et al.   CELL

mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway

(2011) Timothy R. Peterson et al.   CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling

(2011) Y. Yu et al.   SCIENCE

The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling

(2011) P. P. Hsu et al.   SCIENCE

Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance

(2011) K. Tanaka et al.   Cancer Discovery

Mammalian Target of Rapamycin Protein Complex 2 Regulates Differentiation of Th1 and Th2 Cell Subsets via Distinct Signaling Pathways

(2010) Keunwook Lee et al.   IMMUNITY

Requirement of the mTOR Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in Cancer Cells

(2010) Boris Shor et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1

(2010) Katrin Düvel et al.   MOLECULAR CELL

mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1

(2010) T. Kantidakis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs

(2010) R. J. O. Dowling et al.   SCIENCE

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

(2009) David A. Guertin et al.   CANCER CELL

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

(2009) K. Yu et al.   CANCER RESEARCH

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

(2009) H. A. Lane et al.   CLINICAL CANCER RESEARCH

The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment

(2009) Greg M. Delgoffe et al.   IMMUNITY

mTOR regulates memory CD8 T-cell differentiation

(2009) Koichi Araki et al.   NATURE

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth

(2008) Thomas Porstmann et al.   Cell Metabolism

Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation

(2008) Audrey Carrière et al.   CURRENT BIOLOGY

The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1

(2008) Y. Sancak et al.   SCIENCE